Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
Jessica L Norman, Sarah L Anderson Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA Abstract: Insomnia, a highly prevalent disorder, can be detrimental to patients’ overall health and worsen existing co...
Guardado en:
Autores principales: | Norman JL, Anderson SL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f5ea8c4db0d84c1db25513681410bbe6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress
por: Chow M, et al.
Publicado: (2016) -
Suvorexant: a promising, novel treatment for insomnia
por: Lee-Iannotti JK, et al.
Publicado: (2016) -
Novel non-pharmacological insomnia treatment – a pilot study
por: Pavlova MK, et al.
Publicado: (2019) -
Sleep-Wake Survival Dynamics in People with Insomnia
por: Hermans LWA, et al.
Publicado: (2021) -
Hyperarousal and sleep reactivity in insomnia: current insights
por: Kalmbach DA, et al.
Publicado: (2018)